Cargando…
A general evidence-based sequence variant control limit for recombinant therapeutic protein development
Sequence variants (SVs) resulting from unintended amino acid substitutions in recombinant therapeutic proteins have increasingly gained attention from both regulatory agencies and the biopharmaceutical industry given their potential impact on efficacy and safety. With well-optimized production syste...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531532/ https://www.ncbi.nlm.nih.gov/pubmed/32744138 http://dx.doi.org/10.1080/19420862.2020.1791399 |